The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER).
Pan-Chyr Yang
No relevant relationships to disclose
Yuankai Shi
No relevant relationships to disclose
Joseph Siu-kie Au
No relevant relationships to disclose
Sankar Srinivasan
No relevant relationships to disclose
Gerardo H. Cornelio
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Chun-Ming Tsai
No relevant relationships to disclose
Sumitra Thongprasert
Consultant or Advisory Role - Lilly (U); Novartis (U); Pfizer (U)
Honoraria - AstraZeneca; Roche
Research Funding - Novartis; Pfizer; Roche
Dr Karin Heeroma
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Itoh Yohji
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Mai Trong Khoa
No relevant relationships to disclose